Medical Device News Magazine

Research Published in JSES Indicates that the Catalyst™ CSR Total Shoulder System Outperforms Traditional Stemmed Implants

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has announced the publication of a new study in the Journal of Shoulder and Elbow Surgery that shows positive clinical outcomes using the Catalyst™ CSR total shoulder system, compared to standard stemmed TSAs.

The study, Stemless Total Shoulder Arthroplasty Using a Novel Multiplanar Osteotomy and Elliptical Humeral Head Results in Both Improved Early Range of Motion and Radiographic Center of Rotation Compared to Standard Total Shoulder Arthroplasty (Budge, Orvets), tested and compared early postoperative range of motion (ROM) and restoration of radiographic center of rotation (COR), using the Catalyst anatomic shoulder system and standard stemmed TSAs.

The results demonstrate that patients who received the Catalyst anatomic shoulder replacement achieved better ROM at 6 and 12 weeks, and improved restoration of the radiographic COR when compared to patients who received a standard stemmed TSA with a spherical humeral head.

“The Catalyst CSR anatomic shoulder system uses a multiplanar osteotomy that allows for superior precision and accuracy in shoulder replacement, while preserving more of the patient’s native bone,” said Matthew Budge, M.D., orthopedic surgeon, Kaiser Permanente. “This novel approach leverages both reproduction of the patient’s native humeral head height and offset with an ellipsoid anatomic head. Together, these attributes contributed to a faster recovery time compared to standard stemmed TSA.”

This study was a retrospective review of 50 consecutive primary patients by a single surgeon. Data was collected at 6 weeks, 12 weeks, 6 months, and 12 months postoperative on patients who received 25 stemmed implants from Depuy, Stryker (Wright Medical), Lima & Zimmer Biomet and 25 Catalyst anatomic implants.

95% of patients in the Catalyst group had a change in COR <3mm, compared to only 60% in the stemmed group, indicating that the multiplanar osteotomy and ellipsoid anatomic head result in more consistent reproduction of the humeral head anatomy, supporting better ROM.

“Faster recoveries can be attributed to a combination of several factors working in unison,” said Carl O’Connell, CEO and president of Catalyst. “A more anatomically shaped, ellipsoid humeral head design better mimics the patient’s natural anatomy. Our precision multiplanar osteotomy instrumentation removes a minimal amount of bone and consistently allows for better restoration of the native humeral joint line. And patented, oblique glenoid instruments allow for the glenoid to be prepared with less muscle retraction than a traditional perpendicular approach.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”